⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 9, 2024Neurology

Impact of Psychiatric Conditions on the Real-world Effectiveness of Eptinezumab Treatment in Patients with Chronic Migraine (P4-12.005)

Charles E. Argoff Steven Herzog Ryan Smith Seema Soni-Brahmbhatt Susanne F. Awad Divya Asher Fawad Khan

View Full Paper

Ask AI

Bookmark

Share

Abstract

To evaluate whether the presence of psychiatric conditions impacts the real-world effectiveness of eptinezumab in patients with chronic migraine (CM).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Argoff et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdadb6db643587677c9e https://doi.org/10.1212/wnl.0000000000204583

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Real-world Effectiveness of Eptinezumab in Chronic Migraine: A 4-year Retrospective Longitudinal Cohort Study (P10-15.003)Cohort Study · 2026
2Real-world Effectiveness of Intravenous Eptinezumab in Patients with Chronic Migraine and Previous Subcutaneous Preventive Migraine Treatment (P8-12.004)2024
3Treatment with Eptinezumab Reduces Brain Fog and Increases the Number of Good Days Per Month in Patients with Chronic Migraine in a Real-world Setting (P8-12.009)2024 · 1 citations
4Real-world effectiveness and satisfaction with intravenous eptinezumab treatment in patients with chronic migraine: REVIEW, an observational, multi-site, US-based study2024 · 13 citations
5Real-world effectiveness of eptinezumab in chronic migraine—increase in good days in three subgroups: psychiatric comorbidities, prior subcutaneous anti-calcitonin gene-related peptide therapy, and migraine-associated brain fog2025 · 1 citations